Zoomcar Holdings에 대한 매도 수량은 투자자에게 Zoomcar Holdings의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Zoomcar Holdings (NASDAQ:ZCAR) 주식, 공매도 수량 보고

Zoomcar Holdings

Zoomcar Holdings Inc is India's largest marketplace for cars on rent. Zoomcar is a leading emerging-market-focused peer-to-peer car-sharing marketplace, with approximately 21,000 vehicles registered through its platform. The Company derives its revenue principally from short-term self-drive rentals and vehicle subscriptions. The self-drive rental business generates the majority of revenue. Geographically The company operates in India, Egypt, Indonesia, Vietnam, and the Philippines, Out of which the majority of revenue is derived from India.

Zoomcar Holdings Inc

Telsey Advisory Group analyst Cristina Fernandez downgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Outperform to Market Perform and lowers the price target from $93 to $80.

News

Downgrades

Price Target

Analyst Ratings

Telsey Advisory Group Downgrades Nike to Market Perform, Lowers Price Target to $80

Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/FRX#TSX">FRX</a>), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors.
PEDMARQSI&nbsp;is the first and only approved therapy in the EU and&nbsp;U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to &lt;18 years of age with localized, non-metastatic solid tumors. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize&nbsp;PEDMARQSI&#xAE;&nbsp;in&nbsp;Europe,&nbsp;Australia, and New Zealand.
"Securing access to PEDMARQSI is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," said&nbsp;Jeff Hackman, chief executive officer and director of Fennec Pharmaceuticals. "We congratulate Norgine on their collaboration with NICE to reach this important agreement that recognizes the value of ototoxicity intervention as part of the cancer treatment journey."
Under the terms of the <a href="https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-and-norgine-enter-exclusive-licensing">previously announced</a> exclusive licensing agreement with Norgine, Fennec received approximately $43 million in an upfront payment and will receive up to approximately $230 million in additional commercial and regulatory milestone payments along with double-digit tiered royalties on net sales of PEDMARQSI starting in the mid-teens and growing to the mid-twenties.

Government

Regulations

FENC

TSX:FRX

Fennec's PEDMARQSI Gains National Institute for Health and Care Excellence Support, Offers Hope for Young Patients

Elon Musk-led SpaceX&nbsp;on Thursday secured a contract to conduct two additional&nbsp;private astronaut missions to the&nbsp;International Space Station (ISS). These missions will utilize the&nbsp;Falcon 9 rocket and Crew&nbsp;Dragon capsule.
What Happened: SpaceX's Falcon 9 will launch two spaceflight missions for&nbsp;Vast Space, a California-based company.
Vast Space is focused on&nbsp;developing a private space station&nbsp;named Haven-1, which could potentially launch into orbit next year using a Falcon 9 rocket.&nbsp;The company's CEO Max Haot&nbsp;highlighted the significance of these missions in strengthening their collaboration with NASA and other space agencies, according to an announcement by the company.
Haot further mentioned that these missions enhance Vast&#8217;s capabilities&nbsp;in human spaceflight operations and&nbsp;position the company as a strong contender to develop the next-generation ISS successor.
See Also: <a href="https://www.benzinga.com/24/12/42571318/return-of-astronauts-sunita-williams-and-butch-wilmore-from-iss-further-delayed-now-expected-no-earlier-than-late-march">Astronauts Sunita Williams, Butch Wilmore&#8217;s Return From ISS Further Delayed: Now Expected No Earlier Than Late March</a>
Vast is participating in NASA&#8217;s&nbsp;Commercial Low Earth Orbit Destination&nbsp;program with its Haven-2 design, which could be operational by 2028.
While&nbsp;NASA has not yet approved&nbsp;Vast&#8217;s planned missions, SpaceX expressed readiness to proceed once approval is granted. SpaceX President and COO Gwynne Shotwell expressed enthusiasm for working with Vast to expand space travel opportunities.
"I am excited to work with Vast as they build more opportunities and destinations for more people to travel amongst the stars."
Why It Matters: The partnership between SpaceX and Vast Space comes at a time when&nbsp;the Musk-led startup is making significant strides in space exploration.
Recently, SpaceX&#8217;s Starship was <a href="https://www.benzinga.com/general/space/24/11/42151383/elon-musks-spacex-secures-new-moon-mission-contract-after-starships-successful-6th-test-flight">selected by Lunar Outpost</a> to deliver its new moon rover, Eagle, to the lunar surface following a successful suborbital test flight. This highlights SpaceX&#8217;s growing role in lunar exploration.
SpaceX has also been selected to launch <a href="https://www.benzinga.com/general/space/24/11/42181019/spacex-falcon-heavy-to-launch-nasas-dragonfly-mission-to-saturns-largest-moon-in-2028">NASA&#8217;s Dragonfly mission</a> to Saturn&#8217;s largest moon, Titan, in 2028, further cementing its position as a key player in space exploration. This mission, priced at approximately $256.6 million, will utilize the Falcon Heavy rocket, showcasing SpaceX&#8217;s diverse capabilities in launching complex space missions.
However, it hasn't been all smooth sailing for NASA, on the other hand. The agency's plans for the&nbsp;<a href="https://www.benzinga.com/general/space/24/12/42376708/nasa-mission-to-land-humans-on-moon-delayed-artemis-3-now-slated-for-mid-2027">Artemis missions</a>&nbsp;have faced delays, with the Artemis 3 mission now slated for mid-2027.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42575664/tesla-reportedly-in-talks-with-austin">Tesla Reportedly In Talks With Austin To Bring Autonomous Vehicles To Texas Roads</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

Tech

SpaceX To Launch 2 More Private Astronaut Missions To ISS

PTIX

Protagenic Therapeutics Inc Files For Offering Of Up To 5.84M Shares Of Common Stock By Selling Stockholders

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548" title="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548</a>

NVDA

European Commission On Thursday Announced It Approved The Proposed Acquisition Of Run:ai Labs By NVIDIA

Chardan Capital analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) with a Buy rating and announces Price Target of $20.

Initiation

MNMD

Chardan Capital Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $20

<a href="https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved" title="https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved">https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved</a>

ANSS

SNPS

UK's CMA Said Could Approve Synopsys / Ansys Merger If Competition Concerns Are Resolved

Eshallgo Inc ("Eshallgo" or the "Company") (NasdaqCM: EHGO), one of the leading Chinese office integrator, agent, and service provider, and the investment fund CS Asia Opportunities Master Fund (hereinafter referred to as "CS Fund") jointly announced a landmark equity investment. According to the securities purchase agreement between the two parties, CS Fund will become one of the shareholders of EHGO by injecting up to $20 million in equity investment in tranches, demonstrating CS Fund's confidence and high recognition in EHGO's future development prospects.
In this cooperation, CS Fund will purchase a total of up to 4,166,660 shares of EHGO at a price of $4.8 per share in tranches. This strategic move not only provides EHGO with strong financial support but also build momentum in its further business expansion.

EHGO

Eshallgo Announces Major Equity Financing, With Up To $20M To Facilitate Its Entry into Tencent's Business Ecosystem

Until the app's reinstatement, Bigo Live remains unavailable for download on iOS App Store, while its existing users who had previously downloaded the app may continue to use the current version. Apart from the suspension of app availability to new users on iOS App Store as announced in this release, JOYY maintains normal operations globally.
 &nbsp;
 &nbsp;

JOYY Responds To Recent Media Reports; Says Bigo Live Reinstated On Google Play Store, Currently Fully Engaged In Discussions With Apple For Reinstatement To iOS App Store

This not only demonstrates ESHALLGO's steadfast pace in business expansion, officially entering the Tencent business ecosystem, but also signifies that the company will embark on a new mode of cooperation in the fields of office integration services and cloud gaming, jointly exploring this market.

Eshallgo Reveals Acquisition Of D&K Asset Management (Hong Kong) Co., Ltd., And Establishment Of A Deep Strategic Partnership With Beijing Liuliuqiu Cultural Development Co

Amid recent fluctuations, the stock market is showing signs of a potential correction, according to experts. This follows a rebound after a significant selloff, with the&nbsp;S&amp;P 500&nbsp;just 3.6% shy of its all-time high, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>, despite a&nbsp;nearly 3% drop on Wednesday. This decline came after the Federal Reserve updated its inflation and interest rate outlook for 2025.
What Happened: The S&amp;P 500 would need to fall to 5,481 to enter correction territory, which would represent a 10% drop from its peak. The last correction was noted in October 2023, as per Dow Jones Market Data. Despite the recent dip, the S&amp;P 500 has risen 4.6% since Election Day, leading to high valuations, Barron&#8217;s <a href="https://www.barrons.com/amp/articles/stock-market-selloff-correction-b8f34593">reported</a> on Friday. 
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42567950/jim-cramer-warns-of-incredible-panic-as-jerome-powells-cautious-rate-cuts-send-us-stocks-into-freefall?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Of &#8216;Incredible Panic&#8217; As Jerome Powell&#8217;s Hawkish Outlook Send Stocks Into Free Fall: &#8216;People Throwing Away Good And Bad&#8217;</a>
John Bartleman, CEO of TradeStation, suggests that a correction could be beneficial, potentially curbing excessive market exuberance.&nbsp;
"A correction is likely. But there are still a couple of years left in this bull market," he said. 
Nancy Curtin, CIO at AlTi Tiedemann Global, views a correction as a potential buying opportunity. Meanwhile,&nbsp;Bret Kenwell&nbsp;of eToro points out that mild inflation and strong earnings forecasts for 2025 could bolster future market growth.
Analysts are forecasting a 15% increase in S&amp;P 500 profits next year, followed by another 13% rise in 2026.&nbsp;Lule Demmissie&nbsp;of Apex Fintech Solutions considers the current pullback as healthy, emphasizing the robust U.S. economy and sustained investor interest in tech stocks.
Why It Matters: The potential for a market correction is underscored by concerns over U.S. economic growth and corporate earnings. 
Wharton&#8217;s Jeremy Siegel also called the <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42570219/whartons-jeremy-siegel-calls-stock-sell-off-a-healthy-reality-check-market-was-overly-optimistic">stock selloff</a> in recent days a "healthy" reaction to the Federal Reserve's cautious approach regarding interest rate cuts the future.
Brian Arcese of Foord Asset Management has highlighted these issues as <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42133820/potential-healthy-correction-for-an-expensive-market-looms-as-us-economic-growth-and-earnings-slow-says-asset-manager-sp-500-nasdaq-futures-trade-lower-in-premarket">potential catalysts for a correction. </a>Arcese notes that the S&amp;P 500 has been &#8220;expensive for quite a while,&#8221; with a price-to-earnings ratio exceeding 27. He suggests that a correction would be healthy, but it would require a catalyst, such as slowing economic growth or rising inflation, to occur.
Price Action: According to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down by 1.06% while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was down by 1.24%. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42545419/bitcoin-ethereum-dogecoin-stay-muted-before-feds-interest-rate-decision-analyst-says-btc-in-parabolic-phase-reveals-its-duration?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Stay Muted Before Fed&#8217;s Interest Rate Decision: Analyst Says BTC In Parabolic Phase, Reveals Its Duration</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

Markets

General

US Stocks 'Likely' Heading for Correction Amid Recent Volatility, Analyst Says: 'But There Are Still A Couple Of Years Left…'

Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) rose sharply in today's pre-market trading as the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">results for its second quarter</a>.
The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.
FedEx shares jumped 8.7% to $299.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) gained 80.5% to $0.3070 in pre-market trading after the company announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) gained 67.4% to $4.12 in pre-market trading fater jumping more than 60% on Thursday. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.</li>
<li>Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) climbed 62.5% to $0.9576 in pre-market trading.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 52.8% to $4.08 in pre-market trading after jumping 317% on Thursday.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) rose 44.5% to $5.00 in pre-market trading as the company announced the FDA approval of SYMVESS&#x2122; (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma.</li>
<li>Aadi Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) gained 35.3% to $3.14 in pre-market trading after the company secured $100 million PIPE financing and announced the sale of FYARRO for $100 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 26.9% to $1.19 in pre-market trading after the company announced 7.85 million of its shares was acquired by Gilead Sciences.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) rose 17.4% to $8.78 in pre-market trading after dipping over 12% on Thursday.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) gained 11.8% to $27.62 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares tumbled 49.5% to $0.1785 in pre-market trading after the company announced notice of delisting and failure to satisfy continued listing rules.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) declined 36.4% to $7.10 in pre-market trading after jumping around 410% on Thursday.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares fell 26.7% to $0.2998 in pre-market trading after jumping 56% on Thursday. Cara Therapeutics recently announced it entered into an all-stock merger with Tvardi Therapeutics.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares dipped 25.2% to $0.9730 in pre-market trading after climbing 65% on Thursday.</li>
<li>Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) fell 24.5% to $1.57 in today's pre-market trading after reporting third-quarter results.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) dipped 23.6% to $1.94 in pre-market trading. Zoomcar said it launched Zoomcar Cabs, which are affordable car rentals with drivers as a new offering.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) fell 13.1% to $8.66 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Earnings

FEDU

Four Seasons Education Reported First Half Revenue $19M, Up By 117.8% YoY, Adj EPADS Of $0.14

The project is the final asset to be sold from Emeren's Maine pipeline. The Company has brought the project to full commercial operation, achieving a significant milestone in its development.&nbsp;
With this sale, Altus Power will assume ownership and long-term management, utilizing the project to deliver clean, sustainable energy to local communities and support Maine's renewable energy objectives.

Asset Sales

AMPS

Emeren Reports Sale Of Its 2.8 MWdc Solar Project Located In Maine To Altus Power; No Terms Disclosed

The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biological systems.

BRKR

Bruker Reveals 1.2 GHz NMR Spectrometer At Swiss High-field NMR Facility

<ul>
<li>Type Inspection Authorization is considered the final phase of aircraft certification ahead of commercial service</li>
<li>Tests were completed using an FAA-conforming flight deck in a Joby simulator</li>
<li>Company targets 2025 to start TIA flight testing with first FAA-conforming aircraft, currently being built</li>
</ul>

JOBY

Joby Says It Conducts First FAA Testing Under TIA, Begins Final Phase of Certification Program

Canoo's Common Stock will continue to trade on The Nasdaq Capital Market under the existing ticker symbol "GOEV" and will begin trading on a split-adjusted basis when the market opens on December 24, 2024. The new CUSIP number for Canoo's Common Stock following the reverse stock split will be 13803R300.

Stock Split

GOEV

Canoo Plans To Effect 1-For-20 Reverse Stock Split Of Its Common Stock, Effective On December 24, 2024

Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo.
The REDEFINE 1 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 57.3% of patients treated with CagriSema were on the highest dose compared to 82.5% with cagrilintide 2.4 mg and 70.2% with semaglutide 2.4 mg.

Novo Nordisk Says CagriSema Demonstrates Weight Loss In Adults With Obesity Or Overweight In The REDEFINE 1 Trial; Company Says  Trial Achieved Its Primary Endpoint By Demonstrating Weight Loss At Week 68 With CagriSema Versus Placebo

Stifel analyst Thomas Stephan downgrades RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Buy to Hold and lowers the price target from $65 to $40.

RXST

Stifel Downgrades RxSight to Hold, Lowers Price Target to $40

Stifel analyst Chris O'Cull initiates coverage on Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Hold rating and announces Price Target of $42.

Stifel Initiates Coverage On Valvoline with Hold Rating, Announces Price Target of $42

13:27 EST Zoomcar (ZCAR) Holdings Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...

Zoomcar Holdings Inc trading halted, volatility trading pause

13:32 EST Zoomcar (ZCAR) Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

Zoomcar Holdings Inc trading resumes

Zoomcar Holdings GAAP EPS of -$4.43, revenue of $2.25M

09:51 EST Zoomcar (ZCAR) Holdings Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...

09:56 EST Zoomcar (ZCAR) Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zoomcar Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) just reported results for the fourth quarter of 2023.<ul><li>Zoomcar Holdings reported earnings per share of -12 cents.</li><li>The company reported revenue of $2.18 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/zcar-stock-earnings-zoomcar-holdings-for-q4-of-2023/">ZCAR Stock Earnings: Zoomcar Holdings Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZCAR Stock Earnings: Zoomcar Holdings Reported Results for Q4 2023

16:22 EST Zoomcar (ZCAR) files to sell 13.21M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...

Zoomcar files to sell 13.21M shares of common stock for holders

09:48 EST Zoomcar (ZCAR) Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

09:43 EST Zoomcar (ZCAR) Holdings Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...

Zoomcar (ZCAR) has announced the launch of Zoomcar Cabs, as a pilot in Bengaluru, that provides commercial cars with professional drivers. Publishe...

Comments

Zoomcar Holdings

매도 수량

Zoomcar Holdings (NASDAQ:ZCAR) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌